The focal therapy treatment for prostate cancer, offering potential preservation of quality of life, is not routinely available to National Health Service (NHS) patients in the United Kingdom, despite being utilized by prominent figures like Lord Cameron, according to reports in The Times and The Telegraph. Focal therapy targets only the cancerous area of the prostate, unlike traditional treatments such as surgery or radiotherapy which treat the entire gland.
Focal therapy employs various energy sources – including heat, cold, or electric shock – to destroy tumor cells while aiming to minimize damage to surrounding healthy tissue. It is considered an option for cancers confined to the prostate and with a low risk of spreading, as outlined by Cleveland Clinic. Memorial Sloan Kettering Cancer Center describes it as a minimally invasive technique for eliminating slight, localized tumors.
The treatment’s appeal lies in its potential to reduce side effects commonly associated with more aggressive interventions, such as urinary incontinence and erectile dysfunction. According to the Prostate Cancer Foundation, focal therapy is increasingly recognized as a viable option for patients with unifocal cancer – a single area of disease – or where other areas are low-risk and suitable for active surveillance. The use of magnetic resonance imaging (MRI) has been crucial in identifying specific areas for targeted treatment.
However, access to focal therapy on the NHS remains limited. While the exact reasons for this disparity are not detailed in the reports, the availability of the treatment appears to be inconsistent across the UK. The reports highlight a contrast between the care received by individuals who can afford private treatment and that available through the public healthcare system.
Research suggests the effectiveness of focal therapy varies, ranging from 30% to over 95%, depending on factors like tumor location, the specific type of focal therapy used, and the criteria for defining success, such as PSA levels, MRI findings, and post-treatment biopsies. A study highlighted by European Medical Journal and Oncodaily indicates that salvage focal therapy can match the outcomes of surgery in patients with recurrent prostate cancer.
Johns Hopkins Medicine notes that focal therapy is guided by imaging and biomarkers, allowing for precise targeting and follow-up. MSK experts confirm that a thorough evaluation is required to determine candidacy, ensuring the tumor is small and localized, and that more extensive treatment can be skipped or delayed. Following focal therapy, close monitoring with MRI and prostate needle biopsy is essential to assess treatment success and detect any recurrence.
The reports do not indicate any immediate plans to expand access to focal therapy on the NHS, leaving many patients facing the choice between potentially debilitating side effects from traditional treatments or seeking costly private care.
